Telerobotic surgery is transitioning from experimental demonstrations to broader clinical and regulatory development, and SS Innovations International Inc. (NASDAQ: SSII) is emerging as a notable contender in this evolving field. The company's founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, recently told MedTech Dive that robotic surgery is fundamentally a form of teleoperation, with the primary technical challenge being the extent to which distance can be introduced without compromising responsiveness. This perspective underscores the company's strategic focus on remote procedures.
As of September 28, 2026, SS Innovations had reported 195 robotic telesurgeries using its SSi Mantra system, including cardiac procedures and long-distance operations. The installed base of SSi Mantra systems reached 244 units, a 45% increase from the end of 2025, while cumulative procedures climbed to 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. These milestones suggest that telerobotic surgery is gaining acceptance in diverse healthcare markets.
The growing interest in telerobotic surgery is putting SS Innovations International (NASDAQ: SSII) and Dr. Srivastava in an increasingly relevant part of the surgical robotics market. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery while the company pursues U.S. FDA clearance and European Union CE marking to expand into additional international markets. These regulatory milestones are critical for broader adoption, as they would validate the system's safety and efficacy in highly regulated markets.
The implications of SS Innovations' progress are significant for the surgical robotics industry. Telerobotic surgery could address surgeon shortages and improve access to specialized care in remote or underserved regions. However, questions remain about infrastructure requirements, latency issues, and regulatory frameworks. The company's ability to secure FDA and CE approvals will likely determine its competitiveness against larger players like Intuitive Surgical and Medtronic. For investors, SSII's growing procedure volume and installed base signal commercial traction, but regulatory risks persist.
MissionIR, a communications platform, provides syndicated content to enhance visibility for companies like SS Innovations. It is part of the Dynamic Brand Portfolio at IBN, which offers wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. These services aim to connect companies with investors and the public. As telerobotic surgery gains ground, SS Innovations' regulatory progress and clinical outcomes will be key indicators of its long-term potential. The company's newsroom at https://ibn.fm/SSII provides updates on its developments.
